Tandem Diabetes Care, Inc. (TNDM) Given Average Rating of “Hold” by Analysts

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has received an average recommendation of “Hold” from the ten ratings firms that are presently covering the company, MarketBeat reports. Six investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $5.08.

TNDM has been the topic of a number of recent research reports. B. Riley restated a “buy” rating and issued a $5.00 target price on shares of Tandem Diabetes Care in a report on Saturday, March 11th. Northcoast Research restated a “buy” rating on shares of Tandem Diabetes Care in a report on Thursday, March 9th. Zacks Investment Research upgraded Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $2.50 target price on the stock in a report on Tuesday, March 14th. Piper Jaffray Companies restated a “neutral” rating on shares of Tandem Diabetes Care in a report on Thursday, March 30th. Finally, Wedbush restated an “outperform” rating and issued a $11.00 target price on shares of Tandem Diabetes Care in a report on Thursday, March 30th.

Tandem Diabetes Care (NASDAQ TNDM) opened at 0.85 on Tuesday. The company’s 50-day moving average price is $0.87 and its 200-day moving average price is $1.70. Tandem Diabetes Care has a one year low of $0.76 and a one year high of $8.81. The firm’s market cap is $42.36 million.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its earnings results on Thursday, April 27th. The medical device company reported ($0.75) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.66) by $0.09. The company had revenue of $17.50 million during the quarter, compared to analyst estimates of $15.72 million. Tandem Diabetes Care had a negative return on equity of 1,177.11% and a negative net margin of 104.31%. The business’s revenue was down 12.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.68) earnings per share. On average, analysts anticipate that Tandem Diabetes Care will post ($1.88) EPS for the current year.

In other Tandem Diabetes Care news, CEO Kim D. Blickenstaff purchased 1,600,000 shares of the stock in a transaction dated Thursday, March 23rd. The shares were acquired at an average price of $1.25 per share, for a total transaction of $2,000,000.00. Following the completion of the acquisition, the chief executive officer now owns 2,007,939 shares of the company’s stock, valued at approximately $2,509,923.75. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 37.10% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Granite Investment Partners LLC increased its position in shares of Tandem Diabetes Care by 29.9% in the first quarter. Granite Investment Partners LLC now owns 448,921 shares of the medical device company’s stock worth $539,000 after buying an additional 103,365 shares in the last quarter. Keybank National Association OH increased its position in shares of Tandem Diabetes Care by 217.9% in the first quarter. Keybank National Association OH now owns 221,029 shares of the medical device company’s stock worth $265,000 after buying an additional 151,492 shares in the last quarter. Frontier Capital Management Co. LLC increased its position in shares of Tandem Diabetes Care by 348.5% in the first quarter. Frontier Capital Management Co. LLC now owns 4,901,870 shares of the medical device company’s stock worth $5,882,000 after buying an additional 3,808,950 shares in the last quarter. Group One Trading L.P. acquired a new position in shares of Tandem Diabetes Care during the first quarter worth $185,000. Finally, A.R.T. Advisors LLC acquired a new position in shares of Tandem Diabetes Care during the fourth quarter worth $116,000. Institutional investors and hedge funds own 73.58% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Mideast Time and is owned by of Mideast Time. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.mideasttime.com/tandem-diabetes-care-inc-tndm-given-average-rating-of-hold-by-analysts/1795025.html.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:TNDM”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Tandem Diabetes Care Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.